Research advances in exosomes in primary biliary cholangitis

Haitao MA; Yingmei TANG

doi:10.3969/j.issn.1001-5256.2022.08.035

Volume 38 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(8): 1896-1900

PDF( 2269 KB)

Research advances in exosomes in primary biliary cholangitis

DOI: 10.3969/j.issn.1001-5256.2022.08.035

Haitao MA,
Yingmei TANG^{,
,}

Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

Research funding:

National Natural Science Foundation of China (81760107);

Natural Science Foundation of Yunnan Province (2018FE001〔-051〕);

Graduate student Innovation Fund of Kunming Medical University (2021S050)

More Information

Corresponding author: TANG Yingmei, tangyingmei_med@kmmu.edu.cn(ORCID:0000-0002-0731-4198)
Received Date: 2021-12-06
Accepted Date: 2022-01-15
Published Date: 2022-08-20

Abstract

Abstract

Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by cholestasis. In recent years, a number of studies in China and globally have shown that exosomes play an important role in the development and progression of PBC, which is currently a hotspot in the field of medical research. This article reviews the role of exosomes in the pathogenesis of PBC and related research advances in the diagnosis and treatment of PBC. It is believed that exosomes have wide application prospect in PBC, and in-depth research on exosomes may bring new opportunities for the diagnosis and treatment of PBC.
- Primary Biliary Cholangitis,
- Exosomes,
- Diagnosis,
- Therapeutics

FullText(HTML)

References(43)

References

[1]	LLEO A, WANG G, GERSHWIN M, et al. Primary biliary cholangitis[J]. Lancet (London, England), 2020, 396(10266): 1915-1926. DOI: 10.1016/S0140-6736(20)31607-X.
[2]	GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7.
[3]	YOKODA RT, CAREY EJ. Primary biliary cholangitis and primary sclerosing cholangitis[J]. Am J Gastroenterol, 2019, 114(10): 1593-1605. DOI: 10.14309/ajg.0000000000000268.
[4]	BANALES JM, HUEBERT RC, KARLSEN T, et al. Cholangiocyte pathobiology[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(5): 269-281. DOI: 10.1038/s41575-019-0125-y.
[5]	PEGTEL DM, GOULD SJ. Exosomes[J]. Annu Rev Biochem, 2019, 88: 487-514. DOI: 10.1146/annurev-biochem-013118-111902.
[6]	JIAO Y, XU P, SHI H, et al. Advances on liver cell-derived exosomes in liver diseases[J]. J Cell Mol Med, 2021, 25(1): 15-26. DOI: 10.1111/jcmm.16123.
[7]	van NIEL G, D'ANGELO G, RAPOSO G. Shedding light on the cell biology of extracellular vesicles[J]. Nat Rev Mol Cell Biol, 2018, 19(4): 213-228. DOI: 10.1038/nrm.2017.125.
[8]	SUNG S, KIM J, JUNG Y. Liver-derived exosomes and their implications in liver pathobiology[J]. Int J Mol Sci, 2018, 19(12): 3715. DOI: 10.3390/ijms19123715.
[9]	DUAN W, ZHANG W, JIA J, et al. Exosomal microRNA in autoimmunity[J]. Cell Mol Immunol, 2019, 16(12): 932-934. DOI: 10.1038/s41423-019-0319-9.
[10]	KALLURI R, LEBLEU VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478): eaau6977. DOI: 10.1126/science.aau6977.
[11]	ANEL A, GALLEGO-LLEYDA A, de MIGUEL D, et al. Role of Exosomes in the regulation of T-cell mediated immune responses and in autoimmune disease[J]. Cells, 2019, 8(2): 154. DOI: 10.3390/cells8020154.
[12]	MIAO C, WANG X, ZHOU W, et al. The emerging roles of exosomes in autoimmune diseases, with special emphasis on microRNAs in exosomes[J]. Pharmacol Res, 2021, 169: 105680. DOI: 10.1016/j.phrs.2021.105680.
[13]	MA WT, CHEN DK. Immunological abnormalities in patients with primary biliary cholangitis[J]. Clin Sci (Lond), 2019, 133(6): 741-760. DOI: 10.1042/CS20181123.
[14]	TOMIYAMA T, YANG GX, ZHAO M, et al. The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis[J]. Cell Mol Immunol, 2017, 14(3): 276-284. DOI: 10.1038/cmi.2015.86.
[15]	CHENG J, WU R, LONG L, et al. miRNA-451a Targets IFN regulatory factor 8 for the progression of systemic lupus erythematosus[J]. Inflammation, 2017, 40(2): 676-687. DOI: 10.1007/s10753-017-0514-8.
[16]	FOTOH DS, NORELDIN RI, RIZK M S, et al. miRNA-451a and miRNA-125a expression levels in ankylosing spondylitis: impact on disease diagnosis, prognosis, and outcomes[J]. J Immunol Res, 2020, 2020: 2180913. DOI: 10.1155/2020/2180913.
[17]	SHEN J, HUANG CK, YU H, et al. The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Cell Mol Med, 2017, 21(5): 986-992. DOI: 10.1111/jcmm.12950.
[18]	AL SURAIH MS, TRUSSONI CE, SPLINTER PL, et al. Senescent cholangiocytes release extracellular vesicles that alter target cell phenotype via the epidermal growth factor receptor[J]. Liver Int, 2020, 40(10): 2455-2468. DOI: 10.1111/liv.14569.
[19]	POPE C, MISHRA S, RUSSELL J, et al. Targeting H19, an imprinted long non-coding RNA, in hepatic functions and liver diseases[J]. Diseases, 2017, 5(1) : 11. DOI: 10.3390/diseases5010011.
[20]	LI X, LIU R, HUANG Z, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans[J]. Hepatology, 2018, 68(2): 599-615. DOI: 10.1002/hep.29838.
[21]	LIU R, LI X, ZHU W, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis[J]. Hepatology, 2019, 70(4): 1317-1335. DOI: 10.1002/hep.30662.
[22]	REUVENI D, BREZIS MR, BRAZOWSKI E, et al. Interleukin 23 produced by hepatic monocyte-derived macrophages is essential for the development of murine primary biliary cholangitis[J]. Front Immunol, 2021, 12: 718841. DOI: 10.3389/fimmu.2021.718841.
[23]	LI X, LIU R, WANG Y, et al. Cholangiocyte-derived exosomal lncRNA H19 promotes macrophage activation and hepatic inflammation under cholestatic conditions[J]. Cells, 2020, 9(1): 190. DOI: 10.3390/cells9010190.
[24]	CHEN S, JIANG T, LIN H, et al. Fast and ultrasensitive visual detection of exosomes in body fluids for point-of-care disease diagnosis[J]. Anal Chem, 2021, 93(29): 10372-10377. DOI: 10.1021/acs.analchem.1c02136.
[25]	SHAO H, IM H, CASTRO CM, et al. New technologies for analysis of extracellular vesicles[J]. Chem Rev, 2018, 118(4): 1917-1950. DOI: 10.1021/acs.chemrev.7b00534.
[26]	JIAO Y, LU W, XU P, et al. Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure[J]. Hepatol Int, 2021, 15(4): 957-969. DOI: 10.1007/s12072-021-10217-3.
[27]	COLAPIETRO F, LIEO A, GENERALI E. Antimitochondrial antibodies: from bench to bedside[J]. Clin Rev Allergy Immunol, 2021, 29: 1-12. DOI: 10.1007/s12016-021-08904-y.
[28]	de RIE D, ABUGESSAISA I, ALAM T, et al. An integrated expression atlas of miRNAs and their promoters in human and mouse[J]. Nat Biotechnol, 2017, 35(9): 872-878. DOI: 10.1038/nbt.3947.
[29]	MORI MA, LUDWIG RG, GARCIA-MARTIN R, et al. Extracellular miRNAs: From biomarkers to mediators of physiology and disease[J]. Cell Metab, 2019, 30(4): 656-673. DOI: 10.1016/j.cmet.2019.07.011.
[30]	OLAIZOLA P, LEE-LAW PY, ARBELAIZ A, et al. MicroRNAs and extracellular vesicles in cholangiopathies[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1293-1307. DOI: 10.1016/j.bbadis.2017.06.026.
[31]	WASIK U, KEMPINSKA-PODHORODECKA A, BOGDANOS DP, et al. Enhanced expression of miR-21 and miR-150 is a feature of anti-mitochondrial antibody-negative primary biliary cholangitis[J]. Mol Med, 2020, 26(1): 8. DOI: 10.1186/s10020-019-0130-1.
[32]	STATELLO L, GUO CJ, CHEN LL, et al. Gene regulation by long non-coding RNAs and its biological functions[J]. Nat Rev Mol Cell Biol, 2021, 22(2): 96-118. DOI: 10.1038/s41580-020-00315-9.
[33]	SHAH R, PATEL T, FREEDMAN JE. Circulating extracellular vesicles in human disease[J]. N Engl J Med, 2018, 379(10): 958-966. DOI: 10.1056/NEJMra1704286.
[34]	GUO N, ZHOU Q, HUANG X, et al. Identification of differentially expressed circulating exosomal lncRNAs in IgA nephropathy patients[J]. BMC Immunol, 2020, 21(1): 16. DOI: 10.1186/s12865-020-00344-1.
[35]	SUN Z, YANG S, ZHOU Q, et al. Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment[J]. Mol Cancer, 2018, 17(1): 82. DOI: 10.1186/s12943-018-0831-z.
[36]	WANG L, ZHANG J. Exosomal lncRNA AK139128 Derived from Hypoxic cardiomyocytes promotes apoptosis and inhibits cell proliferation in cardiac fibroblasts[J]. Int J Nanomedicine, 2020, 15: 3363-3376. DOI: 10.2147/IJN.S240660.
[37]	KHURANA R, RANCHES G, SCHAFFERER S, et al. Identification of urinary exosomal noncoding RNAs as novel biomarkers in chronic kidney disease[J]. RNA, 2017, 23(2): 142-152. DOI: 10.1261/rna.058834.116.
[38]	LI Y, TANG R, MA X. Epigenetics of primary biliary cholangitis[J]. Adv Exp Med Biol, 2020, 1253: 259-283. DOI: 10.1007/978-981-15-3449-2_10.
[39]	RODRIGUES PM, PERUGORRIA MJ, SANTOS-LASO A, et al. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?[J]. J Hepatol, 2018, 69(6): 1371-1383. DOI: 10.1016/j.jhep.2018.08.020.
[40]	GANG D, YU CJ, ZHU S, et al. Application of mesenchymal stem cell-derived exosomes in kidney diseases[J]. Cell Immunol, 2021, 364: 104358. DOI: 10.1016/j.cellimm.2021.104358.
[41]	LOU G, CHEN Z, ZHENG M, et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases[J]. Exp Mol Med, 2017, 49(6): e346. DOI: 10.1038/emm.2017.63.
[42]	RONG X, LIU J, YAO X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway[J]. Stem Cell Res Ther, 2019, 10(1): 98. DOI: 10.1186/s13287-019-1204-2.
[43]	CHEN W, ZHU J, LIN F, et al. Human placenta mesenchymal stem cell-derived exosomes delay H₂O₂-induced aging in mouse cholangioids[J]. Stem Cell Res Ther, 2021, 12(1): 201. DOI: 10.1186/s13287-021-02271-3.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (575) PDF downloads(75)

Research advances in exosomes in primary biliary cholangitis

DOI: 10.3969/j.issn.1001-5256.2022.08.035

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in exosomes in primary biliary cholangitis

DOI: 10.3969/j.issn.1001-5256.2022.08.035

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content